Literature DB >> 29301785

Lp(a) (Lipoprotein(a)) Levels Predict Progression of Carotid Atherosclerosis in Subjects With Atherosclerotic Cardiovascular Disease on Intensive Lipid Therapy: An Analysis of the AIM-HIGH (Atherothrombosis Intervention in Metabolic Syndrome With Low HDL/High Triglycerides: Impact on Global Health Outcomes) Carotid Magnetic Resonance Imaging Substudy-Brief Report.

Daniel S Hippe1, Binh An P Phan1, Jie Sun1, Daniel A Isquith1, Kevin D O'Brien1, John R Crouse1, Todd Anderson1, John Huston1, Santica M Marcovina1, Thomas S Hatsukami1, Chun Yuan1, Xue-Qiao Zhao2.   

Abstract

OBJECTIVE: To assess whether Lp(a) (lipoprotein(a)) levels and other lipid levels were predictive of progression of atherosclerosis burden as assessed by carotid magnetic resonance imaging in subjects who have been treated with LDL-C (low-density lipoprotein cholesterol)-lowering therapy and participated in the AIM-HIGH trial (Atherothrombosis Intervention in Metabolic Syndrome With Low HDL/High Triglycerides: Impact on Global Health Outcomes). APPROACH AND
RESULTS: AIM-HIGH was a randomized, double-blind study of subjects with established vascular disease, elevated triglycerides, and low HDL-C (high-density lipoprotein cholesterol). One hundred fifty-two AIM-HIGH subjects underwent both baseline and 2-year follow-up carotid artery magnetic resonance imaging. Plaque burden was measured by the percent wall volume (%WV) of the carotid artery. Associations between annualized change in %WV with baseline and on-study (1 year) lipid variables were evaluated using multivariate linear regression and the Bonferroni correction to account for multiple comparisons. Average %WV at baseline was 41.6±6.8% and annualized change in %WV over 2 years ranged from -3.2% to 3.7% per year (mean: 0.2±1.1% per year; P=0.032). Increases in %WV were significantly associated with higher baseline Lp(a) (β=0.34 per 1-SD increase of Lp(a); 95% confidence interval, 0.15-0.52; P<0.001) after adjusting for clinical risk factors and other lipid levels. On-study Lp(a) had a similar positive association with %WV progression (β=0.33; 95% confidence interval, 0.15-0.52; P<0.001).
CONCLUSIONS: Despite intensive lipid therapy, aimed at aggressively lowering LDL-C to <70 mg/dL, carotid atherosclerosis continued to progress as assessed by carotid magnetic resonance imaging and that elevated Lp(a) levels were independent predictors of increases in atherosclerosis burden.
© 2018 American Heart Association, Inc.

Entities:  

Keywords:  atherosclerosis; lipids; lipoprotein; lipoprotein(a); lp(a); risk factors; triglycerides

Mesh:

Substances:

Year:  2018        PMID: 29301785      PMCID: PMC5823750          DOI: 10.1161/ATVBAHA.117.310368

Source DB:  PubMed          Journal:  Arterioscler Thromb Vasc Biol        ISSN: 1079-5642            Impact factor:   8.311


  30 in total

1.  Lipoprotein (a) and carotid atherosclerosis in young patients with stroke.

Authors:  Nathalie Nasr; Jean Bernard Ruidavets; Ahmed Farghali; Brigitte Guidolin; Bertrand Perret; Vincent Larrue
Journal:  Stroke       Date:  2011-09-22       Impact factor: 7.914

2.  Mechanisms of lipoprotein(a) pathogenicity: prothrombotic, proatherosclerotic, or both?

Authors:  J David Spence; Marlys Koschinsky
Journal:  Arterioscler Thromb Vasc Biol       Date:  2012-07       Impact factor: 8.311

3.  The ARBITER 6-HALTS Trial (Arterial Biology for the Investigation of the Treatment Effects of Reducing Cholesterol 6-HDL and LDL Treatment Strategies in Atherosclerosis): final results and the impact of medication adherence, dose, and treatment duration.

Authors:  Todd C Villines; Eric J Stanek; Patrick J Devine; Mark Turco; Michael Miller; Neil J Weissman; Len Griffen; Allen J Taylor
Journal:  J Am Coll Cardiol       Date:  2010-06-15       Impact factor: 24.094

4.  Regression of coronary artery disease as a result of intensive lipid-lowering therapy in men with high levels of apolipoprotein B.

Authors:  G Brown; J J Albers; L D Fisher; S M Schaefer; J T Lin; C Kaplan; X Q Zhao; B D Bisson; V F Fitzpatrick; H T Dodge
Journal:  N Engl J Med       Date:  1990-11-08       Impact factor: 91.245

5.  Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy.

Authors:  William E Boden; Jeffrey L Probstfield; Todd Anderson; Bernard R Chaitman; Patrice Desvignes-Nickens; Kent Koprowicz; Ruth McBride; Koon Teo; William Weintraub
Journal:  N Engl J Med       Date:  2011-11-15       Impact factor: 91.245

6.  Determinants of binding of oxidized phospholipids on apolipoprotein (a) and lipoprotein (a).

Authors:  Gregor Leibundgut; Corey Scipione; Huiyong Yin; Matthias Schneider; Michael B Boffa; Simone Green; Xiaohong Yang; Edward Dennis; Joseph L Witztum; Marlys L Koschinsky; Sotirios Tsimikas
Journal:  J Lipid Res       Date:  2013-07-04       Impact factor: 5.922

7.  Arterial Biology for the Investigation of the Treatment Effects of Reducing Cholesterol (ARBITER) 2: a double-blind, placebo-controlled study of extended-release niacin on atherosclerosis progression in secondary prevention patients treated with statins.

Authors:  Allen J Taylor; Lance E Sullenberger; Hyun J Lee; Jeannie K Lee; Karen A Grace
Journal:  Circulation       Date:  2004-11-10       Impact factor: 29.690

Review 8.  Antisense inhibition of apolipoprotein (a) to lower plasma lipoprotein (a) levels in humans.

Authors:  Mark J Graham; Nick Viney; Rosanne M Crooke; Sotirios Tsimikas
Journal:  J Lipid Res       Date:  2015-11-04       Impact factor: 5.922

9.  Extreme lipoprotein(a) levels and risk of myocardial infarction in the general population: the Copenhagen City Heart Study.

Authors:  Pia R Kamstrup; Marianne Benn; Anne Tybjaerg-Hansen; Børge G Nordestgaard
Journal:  Circulation       Date:  2007-12-17       Impact factor: 29.690

10.  Effects of niacin combination therapy with statin or bile acid resin on lipoproteins and cardiovascular disease.

Authors:  Alberto Zambon; Xue-Qiao Zhao; B Greg Brown; John D Brunzell
Journal:  Am J Cardiol       Date:  2014-02-11       Impact factor: 2.778

View more
  12 in total

1.  Highlighting Residual Atherosclerotic Cardiovascular Disease Risk.

Authors:  Yunosuke Matsuura; Jenny E Kanter; Karin E Bornfeldt
Journal:  Arterioscler Thromb Vasc Biol       Date:  2019-01       Impact factor: 8.311

Review 2.  Can Lp(a) Lowering Against Background Statin Therapy Really Reduce Cardiovascular Risk?

Authors:  Željko Reiner
Journal:  Curr Atheroscler Rep       Date:  2019-03-07       Impact factor: 5.113

3.  Race-Based Differences in Lipoprotein(a)-Associated Risk of Carotid Atherosclerosis.

Authors:  Brian T Steffen; George Thanassoulis; Daniel Duprez; James H Stein; Amy B Karger; Mathew C Tattersall; Joel D Kaufman; Weihua Guan; Michael Y Tsai
Journal:  Arterioscler Thromb Vasc Biol       Date:  2019-03       Impact factor: 8.311

4.  Updates on Approaches for Studying Atherosclerosis.

Authors:  Congqing Wu; Alan Daugherty; Hong S Lu
Journal:  Arterioscler Thromb Vasc Biol       Date:  2019-04       Impact factor: 8.311

Review 5.  Lipoprotein(a): An independent, genetic, and causal factor for cardiovascular disease and acute myocardial infarction.

Authors:  Enas A Enas; Basil Varkey; T S Dharmarajan; Guillaume Pare; Vinay K Bahl
Journal:  Indian Heart J       Date:  2019-03-20

6.  Temporal bias in case-control design: preventing reliable predictions of the future.

Authors:  William Yuan; Brett K Beaulieu-Jones; Kun-Hsing Yu; Scott L Lipnick; Nathan Palmer; Joseph Loscalzo; Tianxi Cai; Isaac S Kohane
Journal:  Nat Commun       Date:  2021-02-17       Impact factor: 14.919

7.  Long Noncoding RNA MIAT Controls Advanced Atherosclerotic Lesion Formation and Plaque Destabilization.

Authors:  Francesca Fasolo; Hong Jin; Greg Winski; Valentina Paloschi; Lars Maegdefessel; Ekaterina Chernogubova; Jessica Pauli; Hanna Winter; Daniel Y Li; Nadiya Glukha; Sabine Bauer; Susanne Metschl; Zhiyuan Wu; Marlys L Koschinsky; Muredach Reilly; Jaroslav Pelisek; Wolfgang Kempf; Hans-Henning Eckstein; Oliver Soehnlein; Ljubica Matic; Ulf Hedin; Alexandra Bäcklund; Claes Bergmark
Journal:  Circulation       Date:  2021-10-14       Impact factor: 29.690

8.  The Potential Role of Electronegative High-Density Lipoprotein H5 Subfraction in RA-Related Atherosclerosis.

Authors:  Ching-Kun Chang; Wei-Chung Cheng; Wen-Lung Ma; Po-Ku Chen; Chu-Huang Chen; Pei-Chun Shen; Chia-Ching Chen; Shih-Hsin Chang; Yi-Hua Lai; Der-Yuan Chen
Journal:  Int J Mol Sci       Date:  2021-10-22       Impact factor: 5.923

9.  Assessment of Therapeutic Response to Statin Therapy in Patients With Intracranial or Extracranial Carotid Atherosclerosis by Vessel Wall MRI: A Systematic Review and Updated Meta-Analysis.

Authors:  Pengyu Zhou; Yuting Wang; Jie Sun; Yannan Yu; Mahmud Mossa-Basha; Chengcheng Zhu
Journal:  Front Cardiovasc Med       Date:  2021-10-27

10.  The association of lipoprotein(a) and intraplaque neovascularization in patients with carotid stenosis: a retrospective study.

Authors:  Shuang Xia; Weida Qiu; Anping Cai; Bo Kong; Lan Xu; Zejia Wu; Liwen Li
Journal:  BMC Cardiovasc Disord       Date:  2021-06-09       Impact factor: 2.298

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.